Key Points
- Christine Bellon sold 1,371 shares of Beam on Jan. 22 at an average price of $34 for about $46,614, trimming her stake to 95,667 shares (a 1.41% decrease), per an SEC filing.
- Bellon also executed a larger sale on Jan. 15 of 18,629 shares at an average of $34.61 (≈$644,750), signaling multiple recent insider dispositions.
- For context, Beam (NASDAQ:BEAM) has a market cap of about $3.14B, a 52‑week range of $13.52–$36.44, reported a recent earnings miss with steep negative margins, and carries a MarketBeat consensus rating of Moderate Buy with an average target of $43.80.
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) insider Christine Bellon sold 1,371 shares of the business's stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $34.00, for a total transaction of $46,614.00. Following the completion of the transaction, the insider directly owned 95,667 shares of the company's stock, valued at approximately $3,252,678. This represents a 1.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Christine Bellon also recently made the following trade(s):
- On Thursday, January 15th, Christine Bellon sold 18,629 shares of Beam Therapeutics stock. The shares were sold at an average price of $34.61, for a total transaction of $644,749.69.
Beam Therapeutics Stock Performance
NASDAQ BEAM opened at $30.95 on Tuesday. Beam Therapeutics Inc. has a 52-week low of $13.52 and a 52-week high of $36.44. The company has a fifty day moving average of $27.62 and a 200-day moving average of $23.84. The company has a market capitalization of $3.14 billion, a P/E ratio of -6.99 and a beta of 2.07.
Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.12). Beam Therapeutics had a negative net margin of 744.41% and a negative return on equity of 42.86%. The firm had revenue of $9.70 million for the quarter, compared to analysts' expectations of $12.83 million. During the same quarter in the previous year, the business earned ($1.17) EPS. The company's revenue for the quarter was down 32.2% on a year-over-year basis. As a group, analysts forecast that Beam Therapeutics Inc. will post -4.57 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on BEAM. Benchmark reaffirmed a "speculative buy" rating on shares of Beam Therapeutics in a research note on Monday, November 17th. JPMorgan Chase & Co. cut their price objective on shares of Beam Therapeutics from $48.00 to $46.00 and set an "overweight" rating for the company in a research note on Thursday, October 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Beam Therapeutics in a report on Wednesday, January 21st. Wall Street Zen cut shares of Beam Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, January 11th. Finally, Tudor Pickering set a $41.00 price target on shares of Beam Therapeutics in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $43.80.
View Our Latest Research Report on Beam Therapeutics
Institutional Investors Weigh In On Beam Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC boosted its position in Beam Therapeutics by 15.4% during the 4th quarter. CWM LLC now owns 2,466 shares of the company's stock valued at $68,000 after buying an additional 329 shares during the period. Wealth Effects LLC raised its stake in shares of Beam Therapeutics by 4.3% during the fourth quarter. Wealth Effects LLC now owns 9,600 shares of the company's stock valued at $266,000 after acquiring an additional 400 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Beam Therapeutics by 2.2% during the third quarter. Arizona State Retirement System now owns 26,771 shares of the company's stock worth $650,000 after purchasing an additional 580 shares during the period. Van ECK Associates Corp grew its stake in shares of Beam Therapeutics by 48.7% in the third quarter. Van ECK Associates Corp now owns 2,158 shares of the company's stock worth $52,000 after purchasing an additional 707 shares during the last quarter. Finally, Profund Advisors LLC increased its holdings in Beam Therapeutics by 3.0% during the 2nd quarter. Profund Advisors LLC now owns 26,183 shares of the company's stock valued at $445,000 after purchasing an additional 758 shares during the period. 99.68% of the stock is currently owned by institutional investors.
About Beam Therapeutics
(
Get Free Report)
Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.
Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
